We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Alzheimer's Disease Genetics Study (NCRAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00064870
Recruitment Status : Recruiting
First Posted : July 16, 2003
Last Update Posted : March 1, 2023
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Tatiana Foroud, Indiana University

Brief Summary:
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

Condition or disease
Alzheimer Disease Late Onset Alzheimer Disease Dementia

Detailed Description:
The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
Study Start Date : June 2002
Estimated Primary Completion Date : July 2026
Estimated Study Completion Date : July 2026

Primary Outcome Measures :
  1. Distribute biological specimens to qualified investigators for use in their research studies. [ Time Frame: Contact investigators annually for an update on progress and publication status. ]
    Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies.

Biospecimen Retention:   Samples With DNA
blood samples, brain tissue, cell lines

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Families with two or more members with Alzheimer's disease or dementia

Inclusion Criteria:

  • Two living family members diagnosed with AD or other dementia with any age of onset
  • Biological samples available

    • Fresh blood, or
    • Immortalized lymphoblastic cell lines, or
    • 3-5 grams of frozen cerebral cortex; fixed samples are not accepted

Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.

Exclusion Criteria:

  • Does not meet inclusion criteria
  • Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00064870

Layout table for location contacts
Contact: Study Coordinator 1-800-526-2839 alzstudy@iu.edu

Layout table for location information
United States, Indiana
Participants are being recruited from all over the United States Recruiting
Multiple Locations, Indiana, United States, 46202
Contact: NCRAD Study Coordinator    800-526-2839    alzstudy@iu.edu   
Sponsors and Collaborators
Indiana University
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Tatiana M. Foroud, PhD National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University
Additional Information:
Layout table for additonal information
Responsible Party: Tatiana Foroud, Department Chair, Indiana University
ClinicalTrials.gov Identifier: NCT00064870    
Other Study ID Numbers: IA0042
U24AG021886 ( U.S. NIH Grant/Contract )
NIH grant U24 AG21886
First Posted: July 16, 2003    Key Record Dates
Last Update Posted: March 1, 2023
Last Verified: February 2023
Keywords provided by Tatiana Foroud, Indiana University:
Alzheimer disease
Late Onset Alzheimer disease risk factor genes
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders